• Newsletter
  • Busca
  • Contacto
  • Home (próxima newsletter em preparação)
  • Home
  • News nº 80 | Jun. 2018
  • News nº 81 | Jul. 2018
  • News nº 82 | Set. 2018
  • News nº 83 | Out. 2018
  • News nº 84 | Nov. 2018
  • News nº 85 | Dez. 2018
  • News nº 86 | Jan. 2019
  • News nº 87 | Fev. 2019
  • News nº 88 | Mar. 2019
  • News nº 89 | Abr. 2019
  • News nº 90 | Mai. 2019
  • News nº 91 | jun. 2019
  • News nº 92 | jul. 2019
  • News nº 93 | set. 2019
  • Newsletters
    • 2008 – 2009
      • News nº 1 | nov. 2008
      • News nº 10 | nov/dez. 2009
      • News nº 2 | dez. 2008
      • News nº 3 | jan/fev. 2009
      • News nº 4 | mar. 2009
      • News nº 5 | abr. 2009
      • News nº 6 | mai/jun. 2009
      • News nº 7 | jul. 2009
      • News nº 8 | ago/set. 2009
      • News nº 9 | out. 2009
    • 2010 – 2011
      • News nº 11 | jan/fev. 2010
      • News nº 12 | mar. 2010
      • News nº 13 | abr. 2010
      • News nº 14 | mai. 2010
      • News nº 15 | jun/jul. 2010
      • News nº 16 | ago/set. 2010
      • News nº 17 | out/nov. 2010
      • News nº 18 | dez. 2010
      • News nº 19 | jan/fev. 2011
      • News nº 20 | mar/abr. 2011
      • News nº 21 | mai/jun. 2011
      • News nº 22 | jul/ago. 2011
      • News nº 23 | set/out. 2011
      • News nº 24 | nov/dez. 2011
    • 2012 – 2013
      • News nº 25 | jan. 2012
      • News nº 26 | fev/mar. 2012
      • News nº 27 | jun. 2012
      • News nº 28 | ago. 2012
      • News nº 29 | set/out. 2012
      • News nº 30 | nov/dez. 2012
      • News nº 31 | jan. 2013
      • News nº 32 | mar. 2013
      • News nº 33 | abr. 2013
      • News nº 34 | mai. 2013
      • News nº 35 | jun. 2013
      • News nº 36 | set. 2013
      • News nº 37 | out. 2013
      • News nº 38 | nov/dez. 2013
    • 2014 – 2015
      • News nº 39 | jan/fev. 2014
      • News nº 40 | mar. 2014
      • News nº 41 | abr/mai. 2014
      • News nº 42 | jun/jul. 2014
      • News nº 43 | set. 2014
      • News nº 44 | out/nov. 2014
      • News nº 45 | dez. 2014
      • News nº 46 | jan. 2015
      • News nº 47 | fev. 2015
      • News nº 48 | abr. 2015
      • News nº 49 | mai. 2015
      • News nº 50 | jun. 2015
      • News nº 51 | set. 2015
      • News nº 52 | out. 2015
      • News nº 53 | dez. 2015
    • 2016 – 2017
      • News nº 54 | jan. 2016
      • News nº 55 | fev. 2016
      • News nº 56 | mar. 2016
      • News nº 57 | abr. 2016
      • News nº 58 | mai. 2016
      • News nº 59 | jun. 2016
      • News nº 60 | jul. 2016
      • News nº 61 | set. 2016
      • News nº 62 | out. 2016
      • News nº 63 | nov/dez. 2016
      • News nº 64 | jan. 2017
      • News nº 65 | fev. 2017
      • News nº 66 | mar. 2017
      • News nº 67 | abr. 2017
      • News nº 68 | mai. 2017
      • News nº 69 | jun. 2017
      • News nº 70 | jul. 2017
      • News nº 71 | set. 2017
      • News nº 72 | out. 2017
      • News nº 73 | nov. 2017
      • News nº 74 | dez. 2017
    • 2018
      • News nº 75 | jan. 2018
      • News nº 76 | fev. 2018
      • News nº 77 | mar. 2018
      • News nº 78 | abr. 2018
      • News Nº 79 | Mai. 2018
  • Subscrever Newsletter
My Company
  • Home
  • Newsletters
    • 2018 – 2019
      • News nº 92 | jul. 2019
      • News nº 91 | jun. 2019
      • News nº 90 | Mai. 2019
      • News nº 89 | Abr. 2019
      • News nº 88 | Mar. 2019
      • News nº 87 | Fev. 2019
      • News nº 86 | Jan. 2019
      • News nº 85 | Dez. 2018
      • News nº 84 | Nov. 2018
      • News nº 83 | Out. 2018
      • News nº 82 | Set. 2018
      • News nº 81 | Jul. 2018
      • News nº 80 | Jun. 2018
      • News Nº 79 | Mai. 2018
      • News nº 78 | abr. 2018
      • News nº 77 | mar. 2018
      • News nº 76 | fev. 2018
      • News nº 75 | jan. 2018
    • 2016 – 2017
      • News nº 74 | dez. 2017
      • News nº 73 | nov. 2017
      • News nº 72 | out. 2017
      • News nº 71 | set. 2017
      • News nº 70 | jul. 2017
      • News nº 69 | jun. 2017
      • News nº 68 | mai. 2017
      • News nº 67 | abr. 2017
      • News nº 66 | mar. 2017
      • News nº 65 | fev. 2017
      • News nº 64 | jan. 2017
      • News nº 63 | nov/dez. 2016
      • News nº 62 | out. 2016
      • News nº 61 | set. 2016
      • News nº 60 | jul. 2016
      • News nº 59 | jun. 2016
      • News nº 58 | mai. 2016
      • News nº 57 | abr. 2016
      • News nº 56 | mar. 2016
      • News nº 55 | fev. 2016
      • News nº 54 | jan. 2016
    • 2014 – 2015
      • News nº 53 | dez. 2015
      • News nº 52 | out. 2015
      • News nº 51 | set. 2015
      • News nº 50 | jun. 2015
      • News nº 49 | mai. 2015
      • News nº 48 | abr. 2015
      • News nº 47 | fev. 2015
      • News nº 46 | jan. 2015
      • News nº 45 | dez. 2014
      • News nº 44 | out/nov. 2014
      • News nº 43 | set. 2014
      • News nº 42 | jun/jul. 2014
      • News nº 41 | abr/mai. 2014
      • News nº 40 | mar. 2014
      • News nº 39 | jan/fev. 2014
    • 2012 – 2013
      • News nº 38 | nov/dez. 2013
      • News nº 37 | out. 2013
      • News nº 36 | set. 2013
      • News nº 35 | jun. 2013
      • News nº 34 | mai. 2013
      • News nº 33 | abr. 2013
      • News nº 32 | mar. 2013
      • News nº 31 | jan. 2013
      • News nº 30 | nov/dez. 2012
      • News nº 29 | set/out. 2012
      • News nº 28 | ago. 2012
      • News nº 27 | jun. 2012
      • News nº 26 | fev/mar. 2012
      • News nº 25 | jan. 2012
    • 2010 – 2011
      • News nº 24 | nov/dez. 2011
      • News nº 23 | set/out. 2011
      • News nº 22 | jul/ago. 2011
      • News nº 21 | mai/jun. 2011
      • News nº 20 | mar/abr. 2011
      • News nº 19 | jan/fev. 2011
      • News nº 18 | dez. 2010
      • News nº 17 | out/nov. 2010
      • News nº 16 | ago/set. 2010
      • News nº 15 | jun/jul. 2010
      • News nº 14 | mai. 2010
      • News nº 13 | abr. 2010
      • News nº 12 | mar. 2010
      • News nº 11 | jan/fev. 2010
    • 2008 – 2009
      • News nº 10 | nov/dez. 2009
      • News nº 9 | out. 2009
      • News nº 8 | ago/set. 2009
      • News nº 7 | jul. 2009
      • News nº 6 | mai/jun. 2009
      • News nº 5 | abr. 2009
      • News nº 4 | mar. 2009
      • News nº 3 | jan/fev. 2009
      • News nº 2 | dez. 2008
      • News nº 1 | nov. 2008
  • Subscrever Newsletter
  • Contacto
Main Menu
  • Home
  • Newsletters
    • 2018 – 2019
      • News nº 92 | jul. 2019
      • News nº 91 | jun. 2019
      • News nº 90 | Mai. 2019
      • News nº 89 | Abr. 2019
      • News nº 88 | Mar. 2019
      • News nº 87 | Fev. 2019
      • News nº 86 | Jan. 2019
      • News nº 85 | Dez. 2018
      • News nº 84 | Nov. 2018
      • News nº 83 | Out. 2018
      • News nº 82 | Set. 2018
      • News nº 81 | Jul. 2018
      • News nº 80 | Jun. 2018
      • News Nº 79 | Mai. 2018
      • News nº 78 | abr. 2018
      • News nº 77 | mar. 2018
      • News nº 76 | fev. 2018
      • News nº 75 | jan. 2018
    • 2016 – 2017
      • News nº 74 | dez. 2017
      • News nº 73 | nov. 2017
      • News nº 72 | out. 2017
      • News nº 71 | set. 2017
      • News nº 70 | jul. 2017
      • News nº 69 | jun. 2017
      • News nº 68 | mai. 2017
      • News nº 67 | abr. 2017
      • News nº 66 | mar. 2017
      • News nº 65 | fev. 2017
      • News nº 64 | jan. 2017
      • News nº 63 | nov/dez. 2016
      • News nº 62 | out. 2016
      • News nº 61 | set. 2016
      • News nº 60 | jul. 2016
      • News nº 59 | jun. 2016
      • News nº 58 | mai. 2016
      • News nº 57 | abr. 2016
      • News nº 56 | mar. 2016
      • News nº 55 | fev. 2016
      • News nº 54 | jan. 2016
    • 2014 – 2015
      • News nº 53 | dez. 2015
      • News nº 52 | out. 2015
      • News nº 51 | set. 2015
      • News nº 50 | jun. 2015
      • News nº 49 | mai. 2015
      • News nº 48 | abr. 2015
      • News nº 47 | fev. 2015
      • News nº 46 | jan. 2015
      • News nº 45 | dez. 2014
      • News nº 44 | out/nov. 2014
      • News nº 43 | set. 2014
      • News nº 42 | jun/jul. 2014
      • News nº 41 | abr/mai. 2014
      • News nº 40 | mar. 2014
      • News nº 39 | jan/fev. 2014
    • 2012 – 2013
      • News nº 38 | nov/dez. 2013
      • News nº 37 | out. 2013
      • News nº 36 | set. 2013
      • News nº 35 | jun. 2013
      • News nº 34 | mai. 2013
      • News nº 33 | abr. 2013
      • News nº 32 | mar. 2013
      • News nº 31 | jan. 2013
      • News nº 30 | nov/dez. 2012
      • News nº 29 | set/out. 2012
      • News nº 28 | ago. 2012
      • News nº 27 | jun. 2012
      • News nº 26 | fev/mar. 2012
      • News nº 25 | jan. 2012
    • 2010 – 2011
      • News nº 24 | nov/dez. 2011
      • News nº 23 | set/out. 2011
      • News nº 22 | jul/ago. 2011
      • News nº 21 | mai/jun. 2011
      • News nº 20 | mar/abr. 2011
      • News nº 19 | jan/fev. 2011
      • News nº 18 | dez. 2010
      • News nº 17 | out/nov. 2010
      • News nº 16 | ago/set. 2010
      • News nº 15 | jun/jul. 2010
      • News nº 14 | mai. 2010
      • News nº 13 | abr. 2010
      • News nº 12 | mar. 2010
      • News nº 11 | jan/fev. 2010
    • 2008 – 2009
      • News nº 10 | nov/dez. 2009
      • News nº 9 | out. 2009
      • News nº 8 | ago/set. 2009
      • News nº 7 | jul. 2009
      • News nº 6 | mai/jun. 2009
      • News nº 5 | abr. 2009
      • News nº 4 | mar. 2009
      • News nº 3 | jan/fev. 2009
      • News nº 2 | dez. 2008
      • News nº 1 | nov. 2008
  • Subscrever Newsletter
  • Contacto

UCID – Research Activity

By etavares On 31 Março, 2012 Reportagem / Perfil | 2012 Comentários fechados em UCID – Research Activity No tags

RESEARCH ACTIVITY

 

_Laboratory for the Molecular Diagnosis of Infections Diseases (LDMDI)  – Presentation 

The mission of the LDMDI (head: Professor Emília Valadas) is to promote and develop clinical and translational research in infectious diseases. Located in Santa Maria Hospital,it is associated with the University Clinic of Infectious and Parasitic Diseases, Faculty of Medicine of the University of Lisbon. Clinical Research at the LDMDI began with the study of Mycobacterium tuberculosis latent infection using the ELISPOT assay to determine the production of interferon-gamma in response to ESAT-6 and CFP-10. Determining the serum levels of antiretroviral drugs using HPLC has also been done since 2006. These two research strands continue and are now evolving to other techniques and to the development of in-house tests.

Pharmacogenetics is a new research strand conducted at the LDMDI, in collaboration with the Faculty of Pharmacy of the University of Lisbon and with the Egas Moniz Higher College of Health. Studies on cell immunity in tuberculosis will start later this year, related to particular aspects, namely HIV infection, the role of vitamin D and of its receptor’s polymorphism in the capacity of monocytes-derived macrophages to destroy mycobacteria. This research strand stems from Professor Emília Valadas’ PhD thesis on immunity in tuberculosis conducted at the London School of Hygiene & Tropical Medicine. Contacts with that institution are a great asset to the design of joint projects.

The close collaboration between LDMDI and physicians of the Infectious Diseases Service of HSM has been crucial to the quality of the work performed. A few master degree theses (Master Degree in Emerging Infectious Diseases, FML) and internships for students from other faculties of medicine (FM of the University of the Algarve) have also been conducted at the LDMDI.

_Research and Integrated Treatment of HIV/AIDs and Hepatitis Unit (created in 2011, by dispatch of the Board of Santa Maria Hospital)

_International Networks (University Clinic of Infectious and Parasitic Diseases and Santa Maria Hospital)
_ NEAT (European AIDS Treatment Network) – Sixth Framework Program 6 (FP6) – Partner 7 (FML)
_ NEAT (European AIDS Treatment Network) – NEAT001/ANRS143 trial – ensaio clínico – Hospital de Santa Maria (Coordenador Nacional – Francisco Antunes)

NEAT (European AIDS Treatment Network) – Sixth Framework Program 6 (FP6) – Partner 7 (FML)

NEAT is a network of excellence funded by the European Commission. Its mission is to strengthen Europe’s capacity for HIV clinical research. Its main activities are centred on clinical research (clinical study NEAT 001/ANRS143 HIV and subsidiary studies, the NEAT Hep C/HIV Cohort Network and activities related to training and education.

The Faculty of Medicine of the University of Lisbon (institution 7) is a partner of NEAT. The third postgraduate course on Drug Therapy in HIV infection/AIDS was funded by NEAT, and the Infectious Diseases Service is the National Coordinating Centre of the clinical study NEAT001 and 11 patients were included.

_ EuroSIDA – observational study funded by the European Union (National Coordinator – Francisco Antunes)

EuroSIDA is a prospective observational cohort study of over 16.505 patients monitored in 103 hospitals from 32 European countries, Israel and Argentina. The main purpose of the study is to have access to the impact of antiretrovirals on HIV-infected population living in Europe.

EuroSIDA is funded by the European Union through the BIOMED 1-2, 5th, 6th, and 7th Framework programmes and EuroCoord. In addition to these funds, it received donations from Gilead, Pfizer, BMS, and Merk. The Infectious Diseases Services is the National Coordinator and has 186 patients.

_ INSIGHT (International Network for Strategic Initiatives in Global HIV Trials) – set up in 2006 by the National Institute of Allergy and Infectious Diseases, funded by the University of Minnesota (USA)
_ START (Strategic Timing of AntiRetroviral Therapy) – clinical trial – Santa Maria Hospital (National Coordinator – Francisco Antunes)

_ Other International and national collaboration (responsible Professor Emília Valadas)

ACHIEV2E Collaboration Study Group – started in 2005; it encompasses 12 European centres and one in Africa. Its main objectives are: to assess the response of HIV2 infected patients to antiretroviral treatment, study the natural history of HIV2 infection, determine HIV2 resistance mutations, and prepare international recommendations on the treatment of this infection.

The International HIV Controllers Study is an international study organized by Professor Bruce Walker which brings together several organizations: Massachusetts General Hospital, The Broad Institute of Harvard and MIT, Harvard Medical School, The Ragon Institute of MGH, MIT, and Harvard, SAIC-Frederick, University of KwaZulu-Natal, and University of California, San Francisco. It includes HIV infected patients who, without therapy, can keep low “viral loads”. The main objectives include; to create an international cohort of HIV1 infected persons who can control de infection without resorting to medication; to determine the influence of genetic factors in the control of infection; to define which are innate and adaptive responses in those individuals; to describe the patterns of viral evolution in situations where there is control of infection; to ascertain the contribution of viral fitness in the control of infection.

The Portuguese HIV-2 Study Group is an international study on HIV2 infection, organized by Dr. Ricardo Camacho, from Egas Moniz Hospital, CHLO. Its main objective is to determine which mutations confer HIV2 resistance to antiretrovirals.

The Portuguese Study Group of Co-Infection (GEPCOI) studies viral hepatitis in its various aspects, from epidemiology to treatment. It includes data from most Portuguese hospitals.

Other Projects (responsible Professor Emília Valadas)

2010-2012: HIVCONTROL – Control based on dynamic modelling of HIV-1 infection for therapy design. Foundation for Science and Technology. PTDC/EEA-CRO/100128/2008. In collaboration with the Institute of Systems and Computer Engineering, Research and Development in Lisbon (INESC ID/INESC/IST/UTL).

2010-2012: Characterization and genotyping of Portuguese strains of Francisella tularensis. Foundation for Science and Technology. PTDC/SAU-ESA/104947/2008. In collaboration with the National Health Institute Doctor Ricardo Jorge.
2009/2012: Does malaria increase susceptibility to tuberculosis? The role of malaria-pigment induced immune-suppression. Foundation for Science and Technology. PIC/IC/83214/2007. In collaboration with the Institute of Molecular Medicine, Faculty of Medicine of Lisbon.

2010/2012: Strategies for early detection of renal failure in patients with HIV infection: the new troponin. Funded by ViiV Healthcare.

2010-2012: Diagnosis of Mycobacterium tuberculosis infection in individuals infected with human immunodeficiency virus. Funded by Gilead Sciences.

2012: Evaluation of Mycobacterium tuberculosis infection in patients with kidney disease. In collaboration with Santa Marta Hospital, Lisbon. Master Degree Dissertation (Master Degree in Emerging Infectious Diseases, FML) (Dr. João Furtado).

2012: Toxoplasma gondii infection in schizophrenics followed at HSM/CHLN. Master Degree Dissertation (Master Degree in Emerging Infectious Diseases, FML) (Dr. João Anastácio).

2012-2013: Assessment of cardiovascular risk in HIV1 infected patients. PhD thesis, FML (Dr. António Pais Lacerda).

Projects (responsible Robert Badura)

2011-2013: Cytotoxic activity of TCD8+ cells in patients infected with HIV1 under antiretroviral therapy and with a CD4/CD8 ratio higher than one. Funded by the Portuguese Society of Infectious Diseases and Clinical Microbiology.

2011-2013: Immunological and virological characterization of HIV.1 infected patients undergoing antiretroviral therapy at the time of seroconversion. In collaboration with the Institute of Molecular Medicine. Funded by ViiV Healthcare and Gilead Sciences

Projects (responsible João Paulo Cruz)

2010-2012: GENOFARM, impact of pharmacogenetics in the population pharmacokinetics of antiretroviral agents in patients co-infected with HIV and HBV and/or HCV. PhD thesis, FF, UL (Dr. João Paulo Cruz).

2011-2013: Impact of inter –subject pharmacokinetic variability and genotypic inhibitory quotient in the effectiveness of darunavir in HIV-1 infected patients. Master Degree Dissertation, FML (Dr. Cristina Carvalho).

2012-2014: Relationship between the therapeutic efficacy and plasma concentration of ribavirin in chronic hepatitis C. In collaboration with the Gastroenterology Service of HSM (Professor Rui Marinho).

Share

Pesquisa

Índice – News nº 26 | fev/mar. 2012
 Nota Editorial
 Centro Hospitalar Lisboa Norte – Um dos Projetos Vencedores da Missão Sorriso
 Howard Hughes Medical Institute distingue Cinco Cientistas Portugueses
 Oitava edição das Medalhas de Honra L’Oreal Portugal para as Mulheres na Ciência
 Plenário: Uma nova Universidade de Lisboa
 CUDI – Vertente Ensino
 UCID – Research Activity
 CUDI – Unidades Assistenciais CHLN
 CUDI – Cooperações
 CUDI – Ações Desenvolvidas
 CUDI – Publicações
 CUDI – Experiências
 Estágio Clínico do 6º Ano em Números: de 2000-2001 a 2010-2011 (Parte 2)
 Abertura da Cátedra Calouste Gulbenkian
 Tomada de Posse – Assembleia da Faculdade da Faculdade de Medicina
 Futurália 2012
 Dia do Candidato na FMUL
 Resultados do 15.º Programa “Educação pela Ciência”
 Publicações Científicas
 Investigação Científica desenvolvida por Alunos – Projecto ATAR-VIH
 Cursos de Formação Contínua da Faculdade de Medicina UL- Não Conferentes de Grau Académico
 Mestrados na Faculdade de Medicina da Universidade de Lisboa
 Doutoramentos na Faculdade de Medicina da Universidade de Lisboa
 Defesas de Mestrado e Doutoramento na Área das Doenças Infecciosas
 Clínica Universitária de Doenças Infecciosas – Apresentação
 IN MEMORIAM – Professor Doutor David Ferreira – textos de Homenagem
 Arquivo Biográfico – Professor Doutor José Francisco David Ferreira
 Gabinete de Desporto – Universidade de Lisboa
 Pesquisar Ciência e Saúde
 Um Dia na Faculdade
 Vamos pôr Portugal a Dançar! – De 21 a 29 de abril
 PRÉMIO BIAL 2012
 DIA SOLIDÁRIO – 24 de Abril de 2012
My Company

100 AnosPropriedade e Edição: Faculdade de Medicina da Universidade de Lisboa NIPC: 502662875  Periodicidade: Mensal  Diretor: Prof. Doutor Fausto J. Pinto Conselho Editorial: Prof. Doutor Fausto J. Pinto, Profª. Doutora Ana Sebastião, Prof. Doutor Mamede de Carvalho, Prof. Doutor António Vaz Carneiro, Prof. Doutor Miguel Castanho, Dr. Luís Pereira  Equipa Editorial:  Ana Raquel Moreira, Cristina Bastos, Isabel Varela, Joana Sousa, Maria de Lurdes Barata, Rui Gomes, Sónia Teixeira  Colaboração:  Gabinete de Relações Públicas, Internacionais e Comunicação  Versão Inglesa: AP|PORTUGAL- Language Services  Conceção: Metatexto, Lda. e-mail: news@medicina.ulisboa.pt  Sede do Editor e Sede da Redação: Avenida Prof. Egas Moniz, 1649-028 Lisboa Estatuto Editorial Anotado na ERC 

  • Increase Font
  • Decrease Font
  • Black & White
  • Inverse Colors
  • Highlight Links
  • Regular Font
  • Reset
Real Accessability